Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|9|21|1851-1858

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.9, Iss.21, 2002-11, pp. : 1851-1858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy?

By Gadgeel Shirish M.  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3197-3200

Blackwell Publishing

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Thymidylate synthase inhibitors for non-small cell lung cancer

By Galvani Elena   Peters Godefridus J   Giovannetti Elisa  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1343-1356

Informa Healthcare

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 739-745

Bentham Science Publishers

Access to resources Recommend Favorite